MSFP
KTTA icon

Mark Sheptoff Financial Planning’s Pasithea Therapeutics KTTA Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-166
Closed -$1.59K – 401
2023
Q3 		$1.59K Buy
+166
New +$1.82K ﹤0.01% 343
2022
Q2 		– Sell
-2,400
Closed -$62K – 407
2022
Q1 		$62K Buy
+2,400
New +$60.7K 0.03% 160

Other funds holding KTTA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mark Sheptoff Financial Planning's KTTA Position: Q4 2023 in Review

Mark Sheptoff Financial Planning sold out of Pasithea Therapeutics (KTTA) in Q4 2023, closing a stake of 166 shares — an estimated $1.59K sold.

Mark Sheptoff Financial Planning first reported a position in KTTA in Q1 2022 and held it in 2 quarters. The position peaked at $62K in Q1 2022. 8 funds tracked by Wall St. Rank hold KTTA as of Q4 2023.

  • Mark Sheptoff Financial Planning reported no remaining Pasithea Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 166 Pasithea Therapeutics shares in Q4 2023, an estimated $1.59K.
  • Mark Sheptoff Financial Planning first reported a position in Pasithea Therapeutics in Q1 2022 and held it in 2 quarters.
  • Mark Sheptoff Financial Planning's Pasithea Therapeutics position peaked at $62K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2023.

Based on Mark Sheptoff Financial Planning's 13F filing for Q4 2023, filed 9 Feb 2024.